secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001558370-24-016294
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Fortress subsidiary Checkpoint's UNLOXCYT for advanced cSCC
------------------------------------------------------------------------

- FDA approved UNLOXCYT (cosibelimab-ipdl) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) in adults not candidates for curative surgery/radiation.
- UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.
- Approval based on objective response rates and duration of response from Study CK-301-101 (NCT03212404).
- Checkpoint Therapeutics is a majority-controlled subsidiary of Fortress Biotech, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/0001558370-24-016294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024016294/fbio-20241213x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer